UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Negative 70.5%

Neg 70.5% Neu 0% Pos 0%

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.